Characteristics | Primary cohort | Training cohort | Validation cohort | p value |
---|---|---|---|---|
Cases | 920 | 651 | 269 | Â |
BMI (kg/\({m}^{2}\)) | 22.45 (20.32, 24.87) | 22.48 (20.34, 24.97) | 22.41 (20.31, 24.69) | 0.786 |
Neutrophil cells count (× 10^9/L) | 3.49 (2.77, 4.49) | 3.45 (2.76, 4.47) | 3.52 (2.82, 4.58) | 0.555 |
Monocyte cells count (× 10^9/L) | 0.45 (0.35, 0.58) | 0.45 (0.35, 0.58) | 0.45 (0.35, 0.57) | 0.936 |
Lymphocyte cells count (× 10^9/L) | 1.72 (1.35, 2.18) | 1.71 (1.36, 2.15) | 1.76 (1.32, 2.22) | 0.851 |
Platelet count (× 10^9/L) | 197 (150, 251) | 195 (151.5, 251) | 201 (148, 251) | 0.999 |
Total bilirubin (μmol/L) | 13.4 (10, 18) | 13.4 (10, 17.9) | 13 (10, 18.1) | 0.872 |
Albumin (g/L) | 38.79 ± 4.31 | 38.8 ± 4.22 | 38.78 ± 4.52 | 0.963 |
Serum ALT (U/L) | 35 (24, 51.25) | 36 (24, 51) | 34 (23, 54) | 0.705 |
Serum AST (U/L) | 39 (30, 57) | 38 (30, 58.5) | 39 (31, 53) | 0.771 |
C-reactive protein (mg/L) | 2.58 (1.2, 7.22) | 2.64 (1.2, 7.19) | 2.44 (1.2, 7.29) | 0.9 |
Prothrombin time (s) | 12.7 (11.9, 13.5) | 12.7 (11.9, 13.5) | 12.7 (12, 13.5) | 0.953 |
Size of tumors (cm) | Â | Â | Â | 0.113 |
  ≤ 3 | 154 (17%) | 117 (18%) | 37 (14%) |  |
 3 − 5 | 255 (28%) | 186 (29%) | 69 (26%) |  |
  > 5 | 511 (56%) | 348 (53%) | 163 (61%) |  |
Sex | Â | Â | Â | 0.208 |
 male | 788 (86%) | 551 (84%) | 238 (88%) |  |
 female | 132 (14%) | 100 (16%) | 31 (12%) |  |
Age (years) | Â | Â | Â | 0.024 |
  < 65 | 791 (86%) | 571 (88%) | 220 (82%) |  |
  ≥ 65 | 129 (14%) | 80 (12%) | 49 (18%) |  |
HBV DNA | Â | Â | Â | 0.232 |
  > 100 IU/ml | 361 (39%) | 264 (41%) | 97 (36%) |  |
  ≤ 100 IU/ml | 559 (61%) | 387 (59%) | 172 (64%) |  |
AFP (ng/mL) | Â | Â | Â | 0.798 |
  ≤ 400 | 567 (62%) | 399 (61%) | 168 (62%) |  |
  > 400 | 353 (38%) | 252 (39%) | 101 (38%) |  |
Cirrhosis | Â | Â | Â | 0.171 |
 Yes | 670(73%) | 483(74%) | 187 (70%) |  |
 No | 250 (27%) | 168 (26%) | 82 (30%) |  |
Ascites | Â | Â | Â | 0.371 |
 Yes | 140 (15%) | 104 (16%) | 36 (13%) |  |
 No | 782 (85%) | 547 (84%) | 233 (87%) |  |
Child–Pugh class |  |  |  | 1 |
 A | 858 (93%) | 607 (93%) | 251 (93%) |  |
 B | 62 (7%) | 45 (7%) | 18 (7%) |  |
Number of tumors | Â | Â | Â | 1 |
 Single | 742 (81%) | 525 (81%) | 217 (81%) |  |
 Multiple | 179 (19%) | 127 (19%) | 52 (19%) |  |
Macrovascular invasion | Â | Â | Â | 0.806 |
 Yes | 175 (19%) | 122 (19%) | 53 (20%) |  |
 No | 745 (81%) | 529 (81%) | 216 (80%) |  |
Edmondson-Steiner grade | Â | Â | Â | 0.142 |
 I-II | 433 (47%) | 317 (49%) | 116 (43%) |  |
 III-IV | 487 (53%) | 334 (51%) | 153 (57%) |  |
MVI | Â | Â | Â | 0.343 |
 Yes | 455 (49%) | 329 (51%) | 126 (47%) |  |
 No | 462 (51%) | 322 (49%) | 143 (53%) |  |
BCLC | Â | Â | Â | 0.73 |
 0 | 29 (3%) | 24 (4%) | 6 (2%) |  |
 1 | 593 (64%) | 421 (65%) | 172 (64%) |  |
 2 | 123 (13%) | 85 (13%) | 38 (14%) |  |
 3 | 175 (19%) | 122 (19%) | 53 (20%) |  |
CNLC, n (%) | Â | Â | Â | 0.421 |
 IA | 298 (32%) | 223 (34%) | 75 (28%) |  |
 IB | 319 (35%) | 221 (34%) | 98 (36%) |  |
 IIA | 103 (11%) | 70 (11%) | 33 (12%) |  |
 IIB | 31 (3%) | 20 (3%) | 11 (4%) |  |
 IIIA | 169 (18%) | 117 (18%) | 52 (19%) |  |